None
Quote | Genmab A/S Dkk (OTCMKTS:GNMSF)
Last: | $274.35 |
---|---|
Change Percent: | -1.66% |
Open: | $274.35 |
Close: | $274.35 |
High: | $288.15 |
Low: | $269.75 |
Volume: | 626 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Genmab A/S Dkk (OTCMKTS:GNMSF)
2024-04-03 04:17:15 ET More on Genmab: Genmab: Recent Updates Support The Growth Narrative Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab announces ~$510M worth of share buybacks AbbVie/ Genmab win FDA priority review for lympho...
2024-02-14 16:17:11 ET Genmab A/S (GMAB) Q4 2023 Results Conference Call February 14, 2024 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President and Chief Executive Officer Anthony Mancini - Executive Vice President & COO Anthony Pagano -...
Message Board Posts | Genmab A/S Dkk (OTCMKTS:GNMSF)
Subject | By | Source | When |
---|---|---|---|
Products in development | XenaLives | investorshub | 10/27/2019 2:32:31 PM |
Product pipeline | XenaLives | investorshub | 10/27/2019 2:32:00 PM |
About Genmab A/S | XenaLives | investorshub | 10/27/2019 2:25:49 PM |
$GMXAY largest holding in Blackrock fund: | XenaLives | investorshub | 10/27/2019 2:23:21 PM |
Genmab Announces Phase II Study of Daratumumab in | PennyStock Alert | investorshub | 09/16/2019 12:43:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Genmab A/S Dkk Company Name:
GNMSF Stock Symbol:
OTCMKTS Market:
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY ® ) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or re...